A Programmable DNAzyme for the Sensitive Detection of Nucleic Acids
Angewandte Chemie International Edition · 2024
DOI: 10.1002/anie.202320179 ↗Kurz gefasst
Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2024. Verfasst von Chenzhi Shi und 11 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, Department of Laboratory Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Center for D…. Hauptthemen laut MEDLINE: DNA, Catalytic, MicroRNAs, Biosensing Techniques. Die Arbeit wurde bisher 92-mal zitiert (Crossref) und nennt 117 Literaturangaben. Gefördert von: National Key Research and Development Program of China, National Natural Science Foundation of China.
Abstract (Originalsprache)
Nucleic acids in biofluids are emerging biomarkers for the molecular diagnostics of diseases, but their clinical use has been hindered by the lack of sensitive detection assays. Herein, we report the development of a sensitive nucleic acid detection assay named SPOT ( s ensitive loo p ‐initiated DNAzyme biosens o r for nucleic acid de t ection) by rationally designing a catalytic DNAzyme of endonuclease capability into a unified one‐stranded allosteric biosensor. SPOT is activated once a nucleic acid target of a specific sequence binds to its allosteric module to enable continuous cleavage of molecular reporters. SPOT provides a highly robust platform for sensitive, convenient and cost‐effective detection of low‐abundance nucleic acids. For clinical validation, we demonstrated that SPOT could detect serum miRNAs for the diagnostics of breast cancer, gastric cancer and prostate cancer. Furthermore, SPOT exhibits potent detection performance over SARS‐CoV‐2 RNA from clinical swabs with high sensitivity and specificity. Finally, SPOT is compatible with point‐of‐care testing modalities such as lateral flow assays. Hence, we envision that SPOT may serve as a robust assay for the sensitive detection of a variety of nucleic acid targets enabling molecular diagnostics in clinics.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Molecular Medicine, Department of Laboratory Medicine, Shanghai Key Laboratory for Nucleic Acid Chemistry and Nanomedicine, Center for DNA Information Storage, Renji Hospital, School of Medicine, Shanghai J…
- Department of Biomedical Engineering, Duke University, Durham, North Carolina, 27708, USA.
- Department of Mechanical Engineering and Materials Science, Duke University, Durham, North Carolina, 27708, USA.
- Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, Georgia, 30322, USA.
- School of Chemistry and Chemical Engineering, Frontiers Science Center for Transformative Molecules, Shanghai Key Laboratory for Molecular Engineering of Chiral Drugs, State Key Laboratory of Metal Matrix Composites, Sh…
- College of Chemistry and Molecular Sciences, Wuhan University, Wuhan, Hubei, 430072, China.
ORCID-Profile: Pengfei Wang
Förderung
- National Key Research and Development Program of China
- National Natural Science Foundation of China
Zitieren
APA
Shi, C., Yang, D., Ma, X., Pan, L., Shao, Y., Arya, G., Ke, Y., Zhang, C., Wang, F., Zuo, X., Li, M., & Wang, P. (2024). A Programmable DNAzyme for the Sensitive Detection of Nucleic Acids. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.202320179
Vancouver
Shi C, Yang D, Ma X, Pan L, Shao Y, Arya G, et al. A Programmable DNAzyme for the Sensitive Detection of Nucleic Acids. Angewandte Chemie International Edition. 2024. doi:10.1002/anie.202320179
BibTeX
@article{Shi2024,
author = {Shi, Chenzhi and Yang, Donglei and Ma, Xiaowei and Pan, Li and Shao, Yuanchuan and Arya, Gaurav and Ke, Yonggang and Zhang, Chuan and Wang, Fuan and Zuo, Xiaolei and Li, Min and Wang, Pengfei},
title = {A Programmable DNAzyme for the Sensitive Detection of Nucleic Acids},
journal = {Angewandte Chemie International Edition},
year = {2024},
doi = {10.1002/anie.202320179}
}
EUVIMED